Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis

Exclusion Criteria

• •1. guttate psoriasis, inverse psoriasis or exclusively associated with the face
• •2. Acute progressive psoriasis, and erythroderma tendency
• •3. current (or within 1 year) pregnancy or lactation
• •4. current significant anxiety or depression with the Self-rating Anxiety Scale (SAS) \> 50 or the Self-rating Depression Scale (SDS) \> 53, or with other psychiatric disorders
• •5. With history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which can't be controlled through ordinary treatments. Those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance. Patients with clinical test results listed below: abnormal serum calcium level ( Ca2+ \> 2.9 mmol/L or \< 2 mmol/L);AST or ALT 2 times more than normal upper limit; Creatinine and cystatin C more than normal upper limit; Hemoglobin elevates 20g/L more than normal upper limit,or hemoglobin reduction to anemia; Platelet count less than 75.0\*10\^9/L; White blood cell less than 3.0\*10\^9/L; Or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study
• •6. Patients with malignant tumors, or when they were enrolled with abnormal tumor markers or with other organ dysfunction
• •7. allergy to anything else ever before;
• •8. current registration in other clinical trials or participation within a month;
• •9. topical treatments (i.e. corticosteroids or retinoic acid or Vitamin D analogs ) within 2 weeks; systemic therapy or phototherapy (ultraviolet radiation B,UVB) and psoralen combined with ultraviolet A (PUVA) within 4 weeks; biological therapy within 12 weeks;
• •10. medical conditions assessed by investigators, that are not suitable for this clinical study.